Related Experiment Video

Updated: Aug 15, 2026

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
08:50

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat

Published on: July 3, 2013

Effects of 25-OHD3 on renal function in pediatric patients with chronic renal failure

A T Mazur, M E Norman

    Mineral and Electrolyte Metabolism
    |January 1, 1984
    PubMed

    Insights

    This study found that 25-hydroxycholecalciferol (25-OHD3) did not accelerate renal function decline in pediatric patients with chronic renal failure and renal osteodystrophy over four years. Treatment maintained stable kidney function, showing it

    Area of Science:

    • Pediatric Nephrology
    • Endocrinology
    • Bone Metabolism

    Background:

    • Renal osteodystrophy is a common complication in pediatric chronic renal failure.
    • The safety and efficacy of various vitamin D metabolites in treating this condition remain debated.
    • Concerns exist regarding potential adverse effects of certain vitamin D analogs on renal function.

    Purpose of the Study:

    • To evaluate the long-term effects of 25-hydroxycholecalciferol (25-OHD3) on renal function in pediatric patients with chronic renal failure and renal osteodystrophy.
    • To determine if 25-OHD3 treatment accelerates the decline in kidney function.
    • To assess the safety profile of 25-OHD3 in this vulnerable patient population.

    Main Methods:

    • A 4-year prospective trial involving 19 nondialyzed pediatric patients.
    • Monitoring of serum creatinine and glomerular filtration rates before and during treatment with 25-OHD3.
    • Analysis of renal function changes in patients completing 2, 3, and 4 years of therapy.

    Main Results:

    • Serum creatinine and glomerular filtration rates remained stable in patients completing 2, 3, and 4 years of 25-OHD3 treatment.
    • No acceleration in renal function deterioration was observed during 25-OHD3 therapy compared to expected decline without vitamin D treatment.
    • An initial increase in mean serum creatinine after 1 year was attributed to 5 patients entering the study in the terminal phase of renal deterioration.

    Conclusions:

    • 25-hydroxycholecalciferol (25-OHD3) appears safe for treating renal osteodystrophy in pediatric chronic renal failure patients.
    • This vitamin D metabolite does not adversely affect the rate of renal function decline.
    • Long-term use of 25-OHD3 can be considered in managing renal osteodystrophy without compromising kidney function.

    More Related Videos

    Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats06:38

    Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats

    Published on: March 11, 2016

    A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion09:02

    A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion

    Published on: February 2, 2021

    Related Concept Videos

    Factors Affecting Renal Clearance: Renal Impairment01:17

    Factors Affecting Renal Clearance: Renal Impairment

    Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
    One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
    Renal Failure: Dose Adjustments01:11

    Renal Failure: Dose Adjustments

    In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
    Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
    However, dosage adjustments...
    Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

    Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

    In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
    Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

    Pharmacokinetics in Pediatric Patients: Drug Excretion

    In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
    Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

    Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

    In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
    Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

    Acute Kidney Injury IV: Diagnostic Studies and Prevention

    Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...